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Abstract
Resistance formation is one of the major hurdles in cancer therapy. Metronomic anti-angiogenic treatment of xeno-
grafted prostate cancer tumors in severe combined-immunodeficiency (SCID) mice with cyclophosphamide (CPA)
results in the appearance of resistant tumors. To investigate the complex molecular changes occurring during resis-
tance formation, we performed a comprehensive gene expression analysis of the resistant tumors in vivo. We
observed a multitude of differentially expressed genes, e.g., PAS domain containing protein 1, annexin A3 (ANXA3),
neurotensin, or plasminogen activator tissue (PLAT), when comparing resistant to in vivo passaged tumor samples.
Furthermore, tumor cells from in vivo and in vitro conditions showed a significant difference in target gene expression.
We assigned the differentially expressed genes to functional pathways like axon guidance, steroid biosynthesis, and
complement and coagulation cascades. Most of these genes were involved in anti-coagulation. Up-regulation of anti-
coagulatory ANXA3 and PLAT and down-regulation of PLAT inhibitor serpin peptidase inhibitor clade Awere validated
by quantitative real-time polymerase chain reaction. In contrast, coagulation factor F3 was upregulated, accompanied
by the expression of an altered gene product. These findings give insights into the resistance mechanisms of metro-
nomic CPA treatment, suggesting an important role of anti-coagulation in resistance formation.
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Introduction
Overcoming resistance to chemotherapeutic treatment is one of the
major issues of clinical cancer research nowadays. Up to now, a vari-
ety of molecular mechanisms leading to chemoresistance of cancer
cells has been investigated and new treatment strategies have been
developed. Besides targeted therapy and combinatorial treatments,
anti-angiogenic therapy is another promising option to circumvent
resistance formation. For example, in prostate cancer, the prognosis
for patients with hormone-resistant prostate carcinoma is poor, be-
cause of frequent chemoresistance that is often followed by relapse
and further tumor progression [1,2]. One suggested follow-up ther-
apy for taxane-resistant hormone-resistant prostate carcinoma is the
metronomic treatment with cyclophosphamide (CPA), reviewed by
Emmenegger et al. [3].
The alkylating agent CPA, if given in normal dose, preferably
targets tumor cells. However, if frequent administration of low dose
is carried out (metronomic therapy), it acts as an anti-angiogenic drug,
as reviewed by Kerbel and Kamen [4].
The pivotal targets of anti-angiogenic therapy are not cancer cells
but blood vessels, supplying the tumor with nutrients and oxygen.
Thus, one advantage of anti-angiogenic therapy is that it targets endo-
thelial cells not carrying a malignant phenotype. These cells are not able
to develop resistance to the treatment, like cancer cells do, due to their
genetic instability.
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Studying the mechanisms leading to resistance to anti-angiogenic
therapy is of great interest, as they may differ from resistance to
classic chemotherapy.
Resistance to anti-angiogenic therapy can be classified into four
major groups: 1) evasive resistance, 2) vascular cooption, 3) reduced
vascular dependence, and 4) vascular remodeling [5].
In 2011, Emmenegger et al. pointed out that the applied CPA dose
(maximum dose or metronomic) directly changes the mechanisms
of resistance formation. After treatment of PC3 xenografts with
maximum dose, tumor cells acquired resistance in vivo and in vitro
[5]. However, after metronomic application of CPA, the resistant
phenotype became manifested only in vivo.
Thoenes et al. showed that metronomic CPA therapy of prostate
cancer xenografts has an anti-angiogenic effect. Tumor vessels were
destroyed and blood supply was reduced during the treatment. Tumors
developed a resistance to the therapy regimen without restoring tumor
vessels or vascular mimicry [6]. Isolated tumor cell lines from resistant
tumors revealed their resistant phenotype only upon reimplantation
in vivo but remained sensitive to chemotherapy in cell culture.
In this particular study, a comparative proteome analysis of chemo-
resistant versus parental PC3 cells was performed, suggesting the
involvement of the coagulation inhibitor annexin A3 (ANXA3)
[6]. However, a genome-wide screen of tumors under the far more
relevant in vivo conditions had not yet been performed.
The current study elucidates genetic alterations of CPA-induced
tumor resistance in vivo using a microarray-based approach.
Materials and Methods
Cell Culture
Cell culture media, antibiotics, FBS, and trypsin/EDTA solution
were purchased from Invitrogen/Life Technologies (Carlsbad, CA).
PC3 human prostate carcinoma cells (PC3-wt, ATCC #CRL1435)
and reisolated clones PC3 A3, PC3 D3, and PC3 D4 were cultured
in RPMI 1640 medium supplemented with 10% FBS. Cells were
grown at 37°C in 5% CO2 in a humidified atmosphere. Generation
of these PC3 cell lines was previously described by Thoenes et al. [6].
Briefly, standard PC3 cells (PC3-wt) had been injected into male
severe combined-immunodeficiency (SCID) mice and treated with
a metronomic regimen of CPA (120 mg/kg every 6 days). After a
response phase, tumors restarted growing. Cells of two different
resistant tumors were isolated (PC3 D3 and PC3 D4). Additionally,
a cell line of untreated tumors was established (PC3 A3), representing
an in vivo passaged control cell line [6]. PC3 subclones were cultured
without antibiotics for at least three to four passages before tumor
cell implantation and were harvested when reaching approximately
70% confluence.
In Vivo Experiments
Male SCID mice (CB17/lcr-PrkdcSCID/Crl; 8–10 weeks) were
housed in individually ventilated cages, under specific pathogen-free
conditions, with a 12-hour day/night cycle and food and water
ad libitum. For tumor formation, 1 × 106 cells in 100 μl of phosphate-
buffered saline were injected subcutaneously with a 25-G needle
(Braun) into the flank of SCID mice (five animals per group). PC3-wt,
PC3 A3, PC3 D3, and PC3 D4 cells were injected and grown as
xenografts until they reached a mean volume of 30 mm3. One group
of each PC3 subclone was treated intraperitoneally with 120 mg/kg
CPA (Sigma-Aldrich, St Louis, MO). At 24 hours after CPA appli-
cation, tumors were harvested (for experimental overview, see
Figure W1). Four individual tumors of each group (PC3-wt, PC3
A3, PC3 D3, and PC3 D4) were analyzed in a microarray experiment
[i.e., four human Gene Chip gene 1.0 ST arrays (Affymetrix, Santa
Clara, CA) per group]. All animal procedures were approved and con-
trolled by the local ethics committee and carried out according to the
guidelines of the German law of protection of animal life.
Microarray
Total RNA was isolated from tumor samples using a tissue homog-
enizer (Silent Crusher M, Heidolph, Germany) and the TRIzol method.
Total RNA was checked for purity and integrity (ND-1000; Thermo
Fisher Scientific, Waltham,MA and Bioanalyzer 2100; Agilent Technol-
ogies, Santa Clara, CA), and 100 ng was used for preparation of labeled
probes for microarray hybridization. For this purpose, Affymetrix-
cDNA synthesis and amplification and terminal labeling kits were used
according to the manufacturer’s instruction. Briefly, total RNA was
reversely transcribed into cDNA using T7 promoter–tagged random
primers; cDNAwas amplified by in vitro transcription and again reverse
transcribed. The resulting cDNA was fragmented, terminally labeled,
and finally hybridized to AffymetrixGeneChips (HuGene 1.0 ST arrays,
Affymetrix) and scanned on an Affymetrix GeneChip Scanner 3000.
Data analysis
Raw data were read into the statistical software R [7] and normal-
ized by the robust multichip analysis (RMA) method [8] within the
xps package from Bioconductor [9]. Differentially expressed genes
and scatter plots were generated using the program spotfire (TIBCO).
P values were calculated using the analysis of variance test, and adjusted
P values were calculated with R using the false discovery rate method.
Functional analysis was performed using Database for Annotation,
Visualization and Integrated Discovery (DAVID) Functional Anno-
tation Bioinformatics Microarray Analysis [10]. The description by
Huang et al. [10] specifies the stated P value as the threshold of EASE
score, a modified Fisher Exact P value, for gene enrichment analysis.
It ranges from 0 to 1. Fisher Exact P value = 0 represents perfect
enrichment. Usually, the P value is equal or smaller than .05 to be
considered strongly enriched in the annotation categories.
To determine the species specificity of each microarray, we mapped
all oligonucleotides from the HuGene 1.0 ST array to the mouse
Refseq transcriptome using the ngs mapper Bowtie. We obtained no
perfectly matching hits, only 23 probes with a single mismatch and
130 probes with two mismatches. 25mers with three or more mis-
matches were regarded as not contributing to the measured signal in
a cross-species context. None of the genes that were differentially
expressed had any oligonucleotide probes that could be mapped to
the mouse transcriptome. Thus, we conclude that the results are not
affected by cross-hybridization of host-derived transcripts.
For the identification of alternative splicing, a filtering approach
was used. First, the splice index was calculated by the MiDAS pro-
gram from Affymetrix apt package. Then, genes were plotted on
probe level together with the gene model to verify alternative splicing
by visual inspection.
Quantitative Real-Time Polymerase Chain Reaction
Total RNA was isolated using NucleoSpin RNA Isolation Kit
(Macherey-Nagel, Dueren, Germany) and transcribed with the
Transcriptor High Fidelity cDNA Synthesis Kit (Roche Diagnostics,
Risch, Switzerland) according to manufacturers’ protocols. Quantitative
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real-time polymerase chain reaction (qPCR) was performed using UPL
Probes (Roche) and ProbesMaster (Roche) on a LightCycler 480 System
(Roche) with glyceraldehyde 3-phosphate dehydrogenase (GAPDH ), β-actin,
and B2M as control.
Human primers used include:
β-actin (UPL Probe #64), left: ccaaccgcgagaagatga, right: ccagaggcg-
tacagggatag;
ANXA3 (UPL Probe #29), left: tccggaaagctctgttgact, right: atctt-
gtttggccagatgct;
B2M (UPL Probe #42), left: ttctggcctggaggctatc, right: tcaggaaattt-
gactttccattc;
bone morphogenetic protein receptor type 1B (BMPR1B; UPL Probe
#21), left: tttcatgccttgttgataaaggt, right: gcttgtttaactttttgtttcctctc;
dehydrogenase/reductase member 2 (DHRS2; UPL Probe #4),
left: tgagactatcacctatcgccaag, right: cagcatagtggttggtgtctg;
F3 exons 1and 2 (UPL Probe #15), left: cgccaactggtagacatgg, right:
gctgccacagtatttgtagtgc;
F3 exons 5 and 6 (UPL Probe #2), left: cagacagcccggtagagtgt, right:
ccacagctccaatgatgtagaa;
GAPDH (UPL Probe #60), left: ctctgctcctcctgttcgac, right: gcccaa-
tacgaccaaatcc;
Neurotensin (NTS; UPL Probe #17), left: cagcttgtatgcatgctactcc,
right: aatgctttcatttcctcttctga;
PAS domain containing protein 1 (PASD1; UPL Probe #20), left:
caacccacctaccatcaggt, right: ctgctccgcagat ctcatc;
plasminogen activator tissue (PLAT; UPL Probe #59), left: cgggt-
ggaatattgctggt, right: cttggctcgctgcaactt;
protein Sα (PROS1; UPL Probe #46), left: acatacctgggtggccttc,
right: tccagatccaactgtacaccat;
special AT-rich sequence-binding protein-1 (SATB1; UPL Probe
#44), left: aatggcattgctgtctctagg, right: actttccaacctggattagcc;
serpin peptidase inhibitor clade A, member 1 (SERPINA1; UPL
Probe #73), left: gcttaaatacggacgaggaca, right: acgagacagaagacggcatt;
serpin peptidase inhibitor clade D, member 1 (SERPIND1; UPL
Probe #29), left: tggtggagagatggcaaaa, right: gattgtagttcttctccagcttgaat;
serine peptidase inhibitor clade B, member 7 (SERPINB7; UPL
Probe #8), left: gattgtagttcttctccagcttgaat, right: caaattgaacttccgttcctg.
Experiments were done in triplicates and the obtained average CT
values of target genes were normalized to control as ΔCT. Changes in
expression levels were shown as fold expression (2−ΔΔCT), calculated
by the ΔΔCT method [11].
Western Blot
After sodium dodecyl sulfate–polyacrylamide gel electrophoresis and
transfer to a nitrocellulose membrane (Bio-Rad Laboratories, Hercules,
CA), the blot was probed with either a goat polyclonal antibody
detecting tissue factor (F3) (1:1000; Santa Cruz Biotechnology, Inc,
Santa Cruz, CA) or with a rabbit monoclonal antibody detecting
GAPDH (1:1000; Cell Signaling Technology, Inc, Cambridge, United
Kingdom) in Tris-buffered saline containing 0.5% Tween and 5%
nonfat milk powder at 4°C overnight. After washing with Tris-
buffered saline containing 0.5% Tween, the membranes were exposed
to horse anti-goat HRP-conjugated secondary antibody (1:10,000;
Vector Laboratories, Burlingame, CA) or a mouse anti-rabbit HRP-
conjugated secondary antibody (1:10,000; Vector Laboratories) followed
by a chemiluminescence detection (LumiLight; Roche Diagnostics).
Results
Comprehensive Analysis of Differentially Expressed Genes
To analyze the gene expression of chemoresistant tumor tissue, a
genome-wide microarray of xenografted PC3 tumor cell lines PC3
Figure 1. Gene expression of the resistant tumors PC3 D3 and PC3
D4. (A) Hierarchical clustering on RMA normalized arrays (four
tumors per group). Red, low distance; blue, high distance. Outliners,
marked by an asterisk, are excluded from further data analysis.
(B) Scatter plot of mean normalized gene expression (log2) PC3
D3/PC3 D4 versus PC3 A3. (C) Venn diagram of PC3 D4 versus A3
and PC3 D3 versus A3 differentially expressed genes (cutoff =
0.4 relative expression change) and table including the top 10 of
genes differentially expressed by both PC3 D3 and PC3 D4. Bold,
qPCR-validated genes. (D) Validation of differentially expressed
genes by qPCR (fold expression to control PC3 A3):DHRS2, PASD1,
SATB1 homeobox 1 (SATB1), NTS, and BMPR1B. *P < .05, **P <
.005, ***P < .0005 (t test).
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D3 and PC3 D4, carrying an in vivo resistant prostate cancer geno-
type, was performed. The four PC3 sublines PC3-wt (standard PC3
cells, in vitro cell culture), PC3 A3 (in vivo passaged control cells),
and in vivo resistant cells PC3 D3 and PC3 D4 were injected sub-
cutaneously into SCID mice (for generation of resistant and control
sublines, see Materials and Methods section). After tumor forma-
tion, one group of each PC3 subline was treated with CPA, whereas
the other group was kept untreated. Microarray analysis of four
individual tumors per group was performed using human Gene Chip
gene 1.0 ST arrays (for an overview, see Figure W1).
To detect distances and similarities between different samples,
RMA normalized data were subjected to hierarchical clustering. Here,
we observed distinct clustering of the different cell lines. In contrast, acute
CPA treatment of the different tumors did not induce additional clus-
ters (Figure 1A). Even though this indicates only a minor direct effect of
CPA on the gene expression profile, we depict the scatter plots of dif-
ferentially expressed genes under direct CPA influence in Figure W2, A
to C , and summarized the differential expressed genes in Tables W4 to
W6. The resistant tumor sublines PC3 D3 and PC3 D4 showed a close
relation of their gene expression profile, suggesting a similar resistance
Figure 1. (continued).
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genotype. Furthermore, in vivo passaging strongly influenced the gene
expression profile. When comparing PC3-wt, the in vitro passaged
subline, with PC3 A3 (in vivo passaged), we found, for example,
ceruloplasmin strongly downregulated. In contrast reelin, an extra-
cellular matrix serine protease, is one of the upregulated genes, demon-
strating the influence of the tumor environment in vivo (Figure W2D
and Tables W7 and W8).
Further analyses were focused on the inherent differences between
samples of resistant cell lines PC3 D3 and PC3 D4 versus in vivo
passaged cell line PC3 A3 without the direct influence of CPA. A
scatter plot of the mean of the normalized gene expression of PC3
D3 and PC3 D4 versus PC3 A3 shows the 50 most differentially
expressed genes (Figure 1B).
Analysis of PC3 D3 versus PC3 A3 and PC3 D4 versus PC3 A3
revealed 415 differentially expressed genes for PC3 D3 and 566 for
PC3 D4. An intersecting set of 212 genes was differentially expressed
in both resistant tumor lines (Figure 1C and Table W1). The most
differentially regulated genes DHRS2, PASD1, and NTS as well as
resistance-related genes like SATB1 and BMPR1B were chosen for fur-
ther analysis. The expression of DHRS2, PASD1, and SATB1 was
increased in the resistant tumors compared to PC3 A3 tumors, whereas
NTS and BMPR1B expression was decreased in resistant tissue.
Validation by qPCR confirmed all five genes as differentially
expressed (Figure 1D). DHRS2 had a 7.1-fold increased expression
level in PC3 D3 and 11.1-fold in PC3 D4 compared to PC3 A3.
PASD1 showed an expression change of 11.7-fold in PC3 D3 and
9.1-fold in PC3 D4 compared to PC3 A3. Additionally SATB1
showed higher expression levels in PC3 D3 (2.4-fold) and PC3
D4 (2.3-fold). Expression of NTS was clearly reduced in resistant
sublines, PC3 D3 and PC3 D4 (five-fold). In contrast, BMPR1B
expression was significantly decreased only in PC3 D4 samples.
To evaluate the in vivo versus the in vitro expression, we analyzed
these five genes under cell culture conditions. Comparing the results,
the in vitro expression clearly differed from the in vivo expression of
all five genes (Figure W3).
Analysis of Involved Pathways
To identify which pathways might be involved in resistance for-
mation, a Kyoto Encyclopedia of Genes and Genomes (KEGG)
pathway analysis was performed using DAVID Functional Annota-
tion Bioinformatics Microarray Analysis [10]. This method revealed
a potential involvement of the following three pathways: 1) axon
guidance, 2) steroid biosynthesis, and 3) complement and coagula-
tion cascades (Figure 2A).
As blood flowmight play a crucial role during resistance formation to
anti-angiogenic therapy, further analysis was focused on the genes
grouped in complement and coagulation cascades. The expression of
F3, PLAT, and ANXA3 was increased in the resistant tumors, whereas
Figure 2. (A) KEGG pathway analysis of differentially expressed genes (cutoff = 0.4 relative expression change). (B) Overview of fold
expression of coagulation pathway–associated genes.
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the expression of PROS1, SERPIND1, SERPINA1, and SERPINB7
was decreased (Figure 2B). Additionally, the two differentially expressed
coagulation genes ANXA3 and SERPINB7 were added to this group,
although their regulation was below the cutoff.
Gene Expression of Coagulation-Related Genes Is Modulated
in Resistant Tumors
qPCR analysis of these coagulation-related genes confirmed the gene
expression profiles obtained by microarray analysis. First, we analyzed
the mRNA expression of the coagulation-promoting proteins. The
coagulation-promoting genes SERPINA1, SERPIND1, SERPINB7,
and PROS1 were downregulated in resistant tumors. In contrast, the
expression level of F3 was slightly increased in PC3 D3 tumor tissue
and displayed a very high expression in PC3 D4 tumor tissue.
Moreover, mRNA expression of proteins hampering coagulation
(PLAT and ANXA3) was increased in PC3 D3 and PC3 D4 tumor
tissue compared to PC3 A3 control tissue (Figure 3A).
When analyzing the gene expression of in vitro cultured cell lines, we
observed a different pattern. F3, PLAT, and ANXA3 showed no altered
gene expression in PC3 D3 and PC3 D4 versus PC3 A3, whereas
the expression profile of SERPINA1, SERPIND1, SERPINB7, and
PROS1 were similarly downregulated in vivo (Figure 3B).
Taken together, genes that encode anti-coagulation proteins were
upregulated and genes that code for proteins promoting coagulation
were downregulated, except F3, in resistant tumor tissue compared to
Figure 3. (A) Validation of coagulation-related genes by qPCR (fold expression to control PC3 A3). (B) Expression of coagulation-related
genes in vitro analyzed by qPCR. *P < .05, **P < .005, ***P < .0005 (t test).
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in vivo passaged control tumors. However, these effects are not present
in vitro.
F3 Exon Structure Is Altered in Resistant PC3 D4 Tumors
F3 is the only candidate that does not fit into the picture of an
anti-coagulative signature in resistant tumors, as it is a coagulation-
promoting gene and highly upregulated in resistant tumor tissue
(34-fold). Therefore, we had a closer look at the exon structure of
F3. The microarray probe setup allowed us to analyze the expression
of a single exon in detail. Comparing resistant PC3 D4 to in vivo
passaged control PC3 A3 tissue, the exon expression profile of F3
shows an altered signal intensity between exons 3 and 6 (Figure 4A),
whereas no differences were detected in exons 1 and 2. This indicates
the expression of different F3 isoforms. Sequencing of the F3 gene
transcript revealed no mutations in the coding sequence (data not
shown). We hypothesized that two different transcripts of the F3 gene
are present, one being prominently expressed in PC3 D4 tumors.
Thus, we analyzed the expression levels of exons 1 and 2 and exons 5
and 6, respectively. In PC3 D4, we observed a higher relative expres-
sion of exons 5 and 6 compared to exons 1 and 2, providing evidence
for the presence of two different F3 transcripts (Figure 4B). Western
blot analysis of the F3 protein expressed by PC3 D4 cell line when cul-
tured in vitro compared to samples from tumor tissue reflects the qPCR
results. In vitro PC3 D4 cells express low levels of F3 protein with a
molecular weight of 47 kDa. On the contrary, in PC3 D4 tumor sam-
ples, two types of F3 protein were observed, one with 47 kDa and an-
other one with a lower molecular weight. The smaller F3 form is more
abundant than the 47-kDa form (Figure 4C ). Overall, we hypothesize
the additional presence of a short form of F3 missing exons 1 and 2 in
resistant tumors in vivo. The loss of these exons might lead to an altered
protein function, helping to maintain the anti-coagulative status.
Figure 3. (continued).
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Discussion
Cells developing resistance to metronomic CPA therapy undergo a
complex molecular evolution. Changes in many different factors
and pathways contribute to the formation of a resistant phenotype.
As shown earlier, most of the classic resistance mechanisms can be
ruled out in this study, as neither increased multi-drug resistance
(MDR) transporter activity nor neoangiogenesis, vascular mimicry,
or impaired CPA activation was observed [6]. A pharmacodynamic
study of metronomically administered CPA suggests that it is unlikely
that resistance to this kind of regimen is caused by impaired CPA
activation [12].
One of the four different categories of resistance to anti-angiogenic
therapy is “reduced vascular dependence.” As shown previously, this
resistance mechanism applies here, as the resistant tumor grows under
conditions of hypoxia and restricted nutrients without the formation
of additional tumor vessels [6]. To investigate the molecular basis of
this in vivo resistance mechanism to anti-angiogenic CPA therapy, a
genome-wide microarray was performed. This study clearly shows
that it is important to use appropriate in vivo controls, as already the
comparison of the gene expression profile of in vivo passaged and stan-
dard PC3 tumors (PC3-wt) displayed a dramatic difference. The gene
expression profile of the standard PC3-wt samples was clearly distinct
from all other in vivo passaged tumor sublines (Figure 1A).
Moreover, gene expression of resistant tumors PC3 D3 and PC3
D4 clearly differed from passaged non-resistant PC3 A3 tumors. An
acute CPA treatment of the respective tumors for 24 hours only influ-
enced gene expression marginally (Figure 1A). All PC3 D3 samples
from four mice clustered in one group, distinct from the PC3 D4
group. Approximately 50% of the differentially expressed genes in
PC3 D3 and PC3 D4 versus PC3 A3 were shared by both resistant
sublines (Figure 1C ). To rule out clonal variation instead of chemo-
resistance as cause of the observed differences, we performed a control
experiment. Here, we compared the initial experiment of PC3 D3 and
PC3 D4 versus PC3 A3 to the control experiments PC3 A3 and PC3
D3 versus PC3 D4 as well as PC3 A3 and PC3 D4 versus PC3 D3 (see
Figure W4, A and B). We could identify less than 2.7% of the genes to
be commonly regulated. Therefore, we regard the signature of resistant
genes as considerable.
Taken together, we assume that not a single main mechanism is
present in the resistant cell lines but more likely a complex molecular
evolution, leading to the ability to survive the restrictive conditions of
anti-angiogenic therapy.
In our model, expression of resistance-related genes in vivo differs
from gene expression in vitro, indicating an involvement of micro-
environmental factors leading to the observed in vivo resistance. The
following three pathways that potentially contribute to the resistant
phenotype were identified: 1) axon guidance, 2) steroid biosynthesis,
and 3) complement and coagulation cascades (Figure 2A). As prostate
cancer cells are able to gain neuronal properties [13,14], neuroendocrine-
like differentiation might take place as a side effect of resistance forma-
tion. Steroid synthesis might be altered leading to hormone-promoted
increased proliferation.
The most interesting functional group is “complement and coag-
ulation cascades.” This group consists of six differentially expressed
genes that are associated with the coagulation cascade. During anti-
angiogenic treatment, blood vessels are destroyed and coagulation
takes place. In mice, the administration of flavone acetic acid, an
anti-angiogenic drug, strongly reduces the coagulation time [15]. We
speculate that resistant tumor cells hamper the coagulation process to
overcome the reduced oxygen and nutrient supply: 1) PLAT (reviewed
in [16]) and 2) ANXA3 [17] showed increased expression in resistant
tumors, whereas expression of pro-coagulation gene PROS1 (reviewed
in [18]) and three members of the serine protease inhibitor family,
1) SERPINA1, 2) SERPINB7, and 3) SERPIND1, were decreased in
resistant tumor tissue. Increased diffusion of oxygen and nutrients is
facilitated by impaired thrombosis and fibrosis. Additionally, metro-
nomic dosing of an inhibitor of systemic vasculogenesis was reported
to cause increased blood flow in luciferase-tagged LM2-4 tumor
xenografts [19].
In contrast to our finding that the expression of anti-coagulation
genes is increased and that of pro-coagulation genes is decreased, F3,
the main mediator of the extrinsic pathway of blood coagulation
[20,21], was highly expressed in PC3 D4 tumor tissue. Interestingly,
F3 shows an altered exon expression profile in PC3 D4 tumor sam-
ples. Comparing expression of PC3 D4 to PC3 A3, exons 3 to 6 are
highly expressed in resistant PC3 D4 tumor tissue, whereas no dif-
ferential expression of exons 1 and 2 can be seen. A version of F3,
missing exons 1 and 2, has not yet been described, whereas an alter-
natively spliced variant of F3, missing exon 5, has been reported [22].
Exons 1 and 2 of F3 are coding for the first 70 amino acids of the
protein. In this area, according to UniProt database [23], a signal
peptide and parts of a topological domain are located. Thus, we
speculate that the expression of an altered F3 protein might result
in an impaired activation of blood coagulation by resistant tumor
tissue or even in facilitating blood flow. Such a hypothesis, however,
remains to be verified by future studies.
Figure 4. (A) Microarray expression profile (probe intensity) of F3
(tissue factor). (B) qPCR of exons 1 and 2 and exons 5 and 6 of
F3. (C) Western blot analysis of F3 in resistant cell line PC3 D4 from
in vitro cell culture samples and in vivo tumor samples.
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In conclusion, resistance formation to metronomic CPA therapy
can be seen as a molecular evolutionary process. Anti-coagulation
properties of the cells (increased PLAT and ANXA3, increased
exon deletion variant of F3, and decreased PROS1, SERPIND1,
SERPINA1, and SERPINB7) could be part of a complex resistance
mechanism. The functional relevance remains to be confirmed by
subsequent studies.
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Figure W1. Schematic overview of the experimental procedure and cell lines used for the in vivo experiments [6].
Figure W2. Scatter plot of mean normalized gene expression (log2) of CPA-treated (24-hour) tumor samples. (A) PC3 A3 + CPA versus
PC3 A3. (B) PC3 D3 + CPA versus PC3 D3. (C) PC3 D4 + CPA versus PC3 D4. (D) PC3-wt versus PC3 A3.
Figure W3. Gene expression of target genes of in vivo differentially
expressed genes in PC3 sublines cultivated in vitro (qPCR, fold
expression to control PC3 A3): DHRS2, PASD1, SATB1 homeobox 1
(SATB1), NTS, and BMPR1B.
Figure W4. Control experiment. Instead of in vivo passaged PC3 A3,
one of the resistant tumors, PC3 D3 or PC3 D4, was taken as control
and compared to the results, where PC3 A3 tumors served as con-
trols. (A) Venn diagram of PC3 A3 and PC3 D3 versus PC3 D4 and
PC3 D3 and PC3 D4 versus PC3 A3. Cutoff = 0.4. Upper diagram,
upregulated genes; lower diagram, downregulated genes. (B) Venn
diagram of PC3 A3 and PC3 D4 versus PC3 D3 and PC3 D3 and PC3
D4 versus PC3 A3. Cutoff = 0.4. Upper diagram, upregulated genes;
lower diagram, downregulated genes.
